ADARx Pharmaceuticals, Inc.

expected

Not yet set

status

Filed with SEC

Industry

Pharmaceutical Preparations

Headquarters

United States

Incorporated in

Underwriters (from filing)

J.P. Morgan Securities LLC, TD Securities (USA) LLC, UBS Securities LLC, LifeSci Capital LLC

Overview

— AI-generated from the filing, see note below

Business overview

ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics aimed at treating a variety of diseases. The company is advancing a pipeline of potent, selective, and durable therapeutic candidates, including three clinical-stage programs targeting complement-mediated diseases, hereditary angioedema, and thrombotic diseases, alongside two advanced preclinical programs targeting obesity and neurodegenerative diseases. ADARx utilizes proprietary technologies to improve siRNA design and delivery for both hepatic and extrahepatic tissue.

Revenue model

Not disclosed in the provided filing text.

Last FY net loss

$73M

Competitive strengths

Proprietary technologies in siRNA design and delivery
Focus on a broad range of diseases with significant unmet needs
Strong clinical-stage therapeutic pipeline

Risk factors

Limited operating history and need for additional capital
High degree of investment risk in biopharmaceutical development
Expectation of significant ongoing and future losses
Dependency on successful completion of clinical trials and regulatory approvals
Need for substantial additional funding for development and commercialization

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

Underwriters on the deal include J.P. Morgan Securities LLC, TD Securities (USA) LLC, UBS Securities LLC, LifeSci Capital LLC. ADARx Pharmaceuticals, Inc. is headquartered in United States and incorporated in DE. It is classified under Pharmaceutical Preparations.

Related IPO lists

Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with ADARx Pharmaceuticals, Inc..

Biotech IPOs United States IPOs J.P. Morgan Securities LLC IPOs TD Securities (USA) LLC IPOs UBS Securities LLC IPOs

Embed this company

Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.

Iframe — WordPress / Ghost / Notion / Webflow

<iframe src="https://www.discoveripo.com/embed/adarx-pharmaceuticals" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="ADARx Pharmaceuticals, Inc. — DiscoverIPO"></iframe>

Dark by default. For a light background, use https://www.discoveripo.com/embed/adarx-pharmaceuticals?theme=light as the src instead.

Share image — Substack, email, anywhere

https://www.discoveripo.com/ipo/adarx-pharmaceuticals/opengraph-image

Attribution text

ADARx Pharmaceuticals, Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/adarx-pharmaceuticals?utm_source=embed&utm_medium=text&utm_campaign=adarx-pharmaceuticals

Track this IPO

Get emailed when ADARx Pharmaceuticals, Inc.'s terms, price, or expected date change — no weekly noise, just this company.

Where this data comes from

Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Sep 14, 2026.

View the original filing on SEC EDGAR →

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.